A commercial path is rarely a single moment. It is a sequence — a visitor moves from an initial page, to a decision point, to a form, to a confirmation, sometimes across five or six structurally distinct steps before a transaction is complete. Where monitoring of that sequence is organized primarily by page or step, each piece of the journey is evaluated against its own threshold, independent of the others. In a great many such reviews, every individual report comes back acceptable — the landing page performs within range, the product page performs within range, the checkout step performs within range. The dashboard, by every measure it contains, is green.

And yet the path's aggregate outcome — the share of visitors who enter at the beginning and complete at the end — can still be disappointing. This is not a contradiction once the underlying mechanics are examined, but it is a genuine surprise to a leadership team accustomed to reading step-level health as a proxy for path-level health. Where monitoring is structured this way, that proxy is not reliable, because steps do not combine the way step-level reporting implicitly assumes they do.

A sequence of steps does not lose value additively. It loses value multiplicatively. If each of five sequential steps independently retains a comfortable majority of visitors who reach it — a result that would look entirely acceptable on any individual step's dashboard — the compounded effect across five such steps can produce a substantially smaller share of visitors reaching the end than any single step's figure would suggest. Each step, reviewed alone, looks fine. The sequence, reviewed as a whole, tells a different story. The arithmetic of sequential loss is unforgiving in a way that step-by-step monitoring, by its nature, does not surface.

This is the structural condition worth naming plainly: where the unit that performance monitoring is built around — the page, the step, the individual touchpoint — is not the unit that commercial outcomes are actually produced by, the monitoring system will faithfully report that everything it is measuring looks fine, while the aggregate journey quietly underperforms in a way no individual report was positioned to catch.

The consequence for leadership, in organizations where monitoring is structured this way, is a specific kind of blind spot. When a path's overall commercial result disappoints, and every step-level dashboard reports green, the natural conclusion is that the underperformance must originate somewhere outside the path itself — in demand, in pricing, in market conditions, in the campaign that drove the traffic. This conclusion is reasonable given the evidence in front of the room, and it may also be incomplete. The evidence in front of the room was built to detect failure at individual points. A sequence that loses substantial value without any individual point ever failing is, to that evidence, invisible.

This has a real cost in how resources get prioritized. A leadership team convinced that its path is healthy — because every step reports as healthy — has little reason to examine the path as a whole. Attention and budget go instead toward demand generation, campaign optimization, or upstream traffic quality, on the theory that the path itself is not the problem. If a meaningful share of the loss is in fact occurring inside the path, compounding quietly across steps that each individually pass inspection, that attention is directed at the wrong layer — repeatedly, because nothing in the monitoring structure signals otherwise.

None of this suggests that step-level monitoring is without value. Individual step health is a legitimate and necessary thing to track. The argument is narrower: step-level health is evidence about steps, not evidence about the path, and where an organization has not separately examined the path as its own unit of analysis, it does not yet know whether a dashboard of green results is describing the thing it actually needs to know about.